ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm
Executive Summary
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
You may also be interested in...
Architect Of Keytruda Reflects On A Great Scientific Success Story
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.
Read-Outs To Look Out For At ESMO Cancer Congress
The European cancer congress returns in-person, with companies big and small presenting new agents and combinations across tumor types.
Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain
Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.